MTOR and T-cell non-Hodgkin lymphoma: Everolimus, an mTOR inhibitor, has demonstrated antiproliferative and antiangiogenic effects in solid tumours and immunosuppressive properties, providing affective in T-cell lymphoma (TCL) with a 44% response rate in relapsed patients [76].